Built for Beagles, Broken for Bears: How America's Veterinary Regulatory Framework Is Failing Exotic and Wildlife Practitioners

A Regulatory Architecture Designed Without Them in Mind

When Congress drafted the foundational statutes governing veterinary drug approval, controlled substance access, and professional licensure, the mental image guiding those deliberations was almost certainly a golden retriever on an examination table or a Holstein heifer in a chute. That assumption was understandable in an era when exotic animal medicine occupied a narrow professional niche. Today, however, it has calcified into policy that actively harms a growing and critically important segment of the veterinary workforce.

Zoological veterinarians, wildlife rehabilitators, sanctuary practitioners, and exotic animal specialists collectively care for thousands of species that no regulatory agency has specifically contemplated. Their patients range from critically endangered black-footed ferrets to common-but-complex reptile cases arriving at suburban wildlife rehabilitation centers. What unites them is a shared experience of practicing at the margins of a system that was never designed to accommodate them — and, in some instances, a system that actively obstructs the care they are trained to provide.

The problem is not a single statute or a single agency. It is architectural. From FDA drug approval pathways to DEA controlled substance registration requirements to state veterinary practice act definitions, the entire regulatory scaffold rests on assumptions about species, practice settings, and patient populations that simply do not hold for exotic and wildlife medicine.

The Off-Label Drug Crisis in Exotic Practice

No regulatory burden is felt more acutely by exotic animal practitioners than the constraints surrounding pharmaceutical access. The FDA approves veterinary drugs for specific species and indications. For dogs, cats, horses, and major food-producing species, that approval landscape — while imperfect — offers practitioners a reasonable formulary. For a veterinarian managing a clouded leopard's post-surgical pain or sedating a great horned owl for wing repair, the approved formulary is essentially empty.

Off-label drug use is legally permissible under the Animal Medicinal Drug Use Clarification Act of 1994, but the practical reality is far more complicated. Compounding pharmacies operating under USP standards face their own regulatory pressures that can limit their willingness or ability to prepare formulations suitable for exotic patients. Controlled substances present an additional layer of complexity: DEA registration requirements were not designed with zoological institutions or field wildlife operations in mind, and the documentation burden for practitioners working in remote rehabilitation settings or during wildlife emergencies can be practically unmanageable.

When a wildlife veterinarian in a field setting cannot access the sedation agent best suited for a particular raptor species — because its only available form requires a compounding process that a registered pharmacy cannot perform under current guidelines — the animal suffers. In some cases, it dies. These are not hypothetical scenarios. They are the daily operational reality for practitioners who have chosen one of veterinary medicine's most demanding specialties.

Licensure Gray Zones and the Jurisdictional Puzzle

Beyond pharmaceuticals, exotic and wildlife practitioners face a jurisdictional complexity that their companion animal and food animal colleagues rarely encounter. State veterinary practice acts define the scope of practice and licensure requirements for veterinarians operating within their borders. Most of those definitions were written with traditional practice settings in mind and have not been meaningfully updated to address the realities of zoological medicine, wildlife rehabilitation, or cross-jurisdictional wildlife response.

Consider the wildlife rehabilitator who holds a state wildlife rehabilitation permit but not a veterinary license, and who must nonetheless make medical decisions for injured animals when no licensed veterinarian is immediately available. Or the zoo veterinarian whose institution operates under federal exhibitor permits from the USDA Animal and Welfare Act program, yet whose state practice act creates ambiguities about certain treatment protocols that do not map cleanly onto the companion animal framework the act was written to govern. Or the veterinarian responding to a multistate wildlife disease event who must navigate different controlled substance reciprocity rules in each jurisdiction crossed during the response.

These are not edge cases confined to a handful of specialists. The American Association of Zoo Veterinarians estimates membership in the thousands, and wildlife rehabilitation organizations operate in every U.S. state. The practitioners at these intersections deserve a regulatory framework that acknowledges their work exists.

Advocacy Efforts Already Underway — and Why They Need Reinforcement

The exotic and wildlife veterinary community has not been passive in the face of these challenges. Professional organizations including the American Association of Zoo Veterinarians, the National Wildlife Rehabilitators Association, and the Association of Reptilian and Amphibian Veterinarians have each engaged in targeted advocacy efforts on specific regulatory pain points. There have been constructive conversations with FDA's Center for Veterinary Medicine about minor species drug access pathways, and the Minor Use and Minor Species Animal Health Act of 2004 created mechanisms — however underutilized — for expanding the approved formulary for non-traditional species.

But these efforts, while meaningful, have remained largely siloed within their respective specialty communities. They have not consistently connected to the broader veterinary advocacy infrastructure, and they have rarely arrived at congressional offices with the organizational weight necessary to move legislation or prompt regulatory guidance updates.

This is precisely where VetPAC's role becomes essential. A unified veterinary advocacy voice — one that carries the credibility of the broader profession while specifically amplifying the concerns of underrepresented specialties — carries substantially more weight in legislative and regulatory settings than any single specialty organization operating alone. When a member of Congress or a senior FDA official understands that exotic and wildlife veterinary concerns are not a fringe interest but an integral part of American veterinary medicine's policy agenda, the conversation changes.

What Meaningful Policy Reform Would Look Like

The policy agenda for exotic and wildlife veterinary medicine is not radical. It is practical, evidence-based, and achievable within existing legislative frameworks if the profession commits to pursuing it with sustained attention.

First, Congress should revisit and strengthen the Minor Use and Minor Species pathways established in 2004, ensuring that the FDA has adequate resources and clear statutory direction to prioritize drug approvals for zoological and wildlife species — particularly those whose conservation status makes treatment access a matter of ecological urgency.

Second, DEA should issue updated guidance — developed in meaningful consultation with zoological and wildlife veterinary practitioners — that addresses the specific operational realities of non-traditional practice settings, including field wildlife response, institutional zoological practice, and rehabilitation facilities.

Third, state veterinary associations and their legislative allies should prioritize modernizing practice act definitions to explicitly address zoological, wildlife, and exotic animal practice, reducing the licensure ambiguities that currently create unnecessary legal exposure for practitioners doing vital work.

None of these steps requires dismantling existing regulatory structures. They require the profession to insist, clearly and consistently, that those structures be updated to reflect the full breadth of veterinary medicine as it is actually practiced in the United States today.

The Profession Cannot Afford Another Cycle of Inaction

Every legislative session that passes without meaningful progress on these issues is another year in which exotic and wildlife practitioners navigate unnecessary obstacles, exotic patients receive suboptimal care, and a generation of veterinary students interested in these specialties inherits a broken framework.

VetPAC's mission — advancing veterinary medicine through advocacy — cannot be fully realized if a significant segment of the profession remains effectively invisible to the policymakers writing the rules. Zoological veterinarians and wildlife practitioners are not asking for special treatment. They are asking to be seen. The profession owes it to them, and to the animals in their care, to make sure Washington finally looks.